Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
Open Access
- 13 February 2019
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2019, 1-4
- https://doi.org/10.1155/2019/6769017
Abstract
Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical trials. We present the unique case of a heavily pretreated mRCC patient with BMs who achieved a brain complete response to cabozantinib prior to receiving radiation therapy. We end with a literature review and discussion of the biologic rationale and growing evidence supporting the intracranial activity of cabozantinib.Keywords
This publication has 24 references indexed in Scilit:
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaBritish Journal of Cancer, 2015
- The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell CarcinomaAmerican Journal of Clinical Oncology, 2013
- Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumClinical Genitourinary Cancer, 2013
- Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase InhibitorsClinical Genitourinary Cancer, 2012
- Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography–tandem mass spectrometry (LC/MS–MS)Journal of Chromatography B, 2012
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysisAnnals of Oncology, 2011
- The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer modelsBreast Cancer Research and Treatment, 2011
- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsAnnals of Oncology, 2011
- Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette TransportersClinical Cancer Research, 2009
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002